AIM
MRNA icon

AHL Investment Management’s Moderna MRNA Stock Holding History

AHL Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25
Closed -$6K – 214
2021
Q4 		$6K Buy
+25
New +$7.31K 0.01% 250

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AHL Investment Management's MRNA Position: Q1 2022 in Review

AHL Investment Management sold out of Moderna (MRNA) in Q1 2022, closing a stake of 25 shares — an estimated $6K sold.

AHL Investment Management first reported a position in MRNA in Q4 2021 and held it in 1 quarter. The position peaked at $6K in Q4 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • AHL Investment Management reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • AHL Investment Management sold 25 Moderna shares in Q1 2022, an estimated $6K.
  • AHL Investment Management first reported a position in Moderna in Q4 2021 and held it in 1 quarter.
  • AHL Investment Management's Moderna position peaked at $6K in Q4 2021.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on AHL Investment Management's 13F filing for Q1 2022, filed 28 Apr 2022.